{
    "nctId": "NCT05804578",
    "briefTitle": "Using a Blood Test to Monitor Metastatic Breast Cancer Treatment",
    "officialTitle": "Using a Liquid Biopsy to Monitor Metastatic Breast Cancer Treatment",
    "overallStatus": "RECRUITING",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 150,
    "primaryOutcomeMeasure": "Change in ctDNA level from baseline to 6 months of treatment",
    "eligibilityCriteria": "Inclusion Criteria\n\n* Adult women (\u2265 18 years of age) with proven diagnosis of adenocarcinoma of the breast with evidence of recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent \\[to be herein described as 'metastatic'\\]\n* De novo metastatic disease or radiographic disease progression on last treatment regimen. Patients already enrolled can be included in a new round if they progress on previous treatment.\n* Planning to start new systemic therapy regimen at discretion of treating physician, per standard of care.\n* Measurable disease as defined by RECIST v.1.1. Tumor lesions previously irradiated or subjected to other locoregional therapy will only be deemed measurable if disease progression at the treated site after completion of therapy is clearly documented.\n* A baseline CT scan must have been done within 6 weeks of entry into the trial\n\nExclusion Criteria\n\n* Patients with exclusive bone metastases (which make up 20-30% of patients), which cannot be evaluated by RECIST, will be excluded except if they have measurable lytic lesions.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}